JPWO2019213245A5 - - Google Patents

Claims (22)

A composition for reducing pathological Tau protein accumulated in a subject, in a pharmaceutically effective amount, 2,4-disulfonylα-phenyltertiary butylnitron (2,4-DSPBN). Or a composition comprising a pharmaceutically acceptable salt thereof and N-acetylcysteine (NAC) or a pharmaceutically acceptable salt thereof. The composition of claim 1, further comprising a pharmaceutically acceptable carrier. The composition according to claim 1, which is orally administered to a subject , intravenously, subcutaneously, sublingually, subdermally, intrathecally, by inhalation, or topically in the ear. The composition according to claim 1, wherein the accumulated pathological Tau protein is due to aging. The composition according to claim 1, wherein the accumulated pathological Tau protein is caused by a central nervous system disease. The composition according to claim 5, which is administered to a subject at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 12 months, or 1 to 60 months after the onset of a central nervous system disease. The composition of claim 1, wherein the accumulated pathological Tau protein results from exposure to noise. The composition according to claim 7, which is administered to a subject at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 12 months, or 1-60 months after exposure to noise . The composition according to claim 1, wherein the accumulated pathological Tau results from exposure to a blast. The composition of claim 9, which is administered to the subject at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 12 months, or 1-60 months after exposure to the blast . The composition according to claim 1, wherein the accumulated pathological Tau is caused by an infection. 11. The composition of claim 11, which is administered to a subject at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 12 months, or 1-60 months after infection . The composition according to claim 1, wherein the accumulated pathological Tau results from exposure to a toxin. 13. The composition of claim 13, which is administered to the subject at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 12 months, or 1-60 months after exposure to the toxin . The composition of claim 1, wherein the subject cerebrospinal fluid comprises at least 0.07 ng / ml of accumulated pathological Tau protein. The composition according to claim 1, wherein the subject suffers from a central nervous system disease and administration of the composition reduces the pathological Tau protein accumulated in the central nervous system by at least 5%. Subject suffers from chronic noise-induced or blast-induced tinnitus or tinnitus, or tinnitus associated with presbycusis or presbycusis, and administration of the composition to the accumulated pathological Tau protein in the cochlea or vestibule. The composition according to claim 1, which is reduced by at least 5%. The composition according to claim 1, further comprising a Tau aggregation inhibitor. The composition according to claim 1, wherein the accumulated pathological Tau protein is a highly phosphorylated form. A composition for reducing pathological Tau protein accumulated in a subject, in a pharmaceutically effective amount, 2,4-disulfonylα-phenyltertiary butylnitron (2,4-DSPBN) or A composition comprising the pharmaceutically acceptable salt thereof. Accumulated pathological Tau is due to exposure to blast or noise and is at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 12 months, or 1-60 months after exposure to blast or noise. The composition according to claim 20, which is administered to a subject. The composition according to claim 20, wherein the accumulated pathological Tau protein is a highly phosphorylated form.